Atlas Trials

Residual Invasive Breast Cancer

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Residual Invasive Breast Cancer

RecordFirmDate
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) (NCT04622319)Daiichi Sankyo2020-12-04

Track Residual Invasive Breast Cancer automatically

Every clearance here is in the API, with alerts when new ones post.